Form 4: Palisade Bio Director Acquires Shares Through Vesting of Restricted Stock Units

Director Binxian Wei of Palisade Bio, Inc. acquired 388 shares of common stock through the vesting of restricted stock units.

Summary

• Binxian Wei, a director at Palisade Bio, Inc., acquired 388 shares of common stock on November 21, 2024.
• The shares were acquired through the vesting of restricted stock units that were granted on November 21, 2023.
• The transaction was reported on November 22, 2024.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed neutrally to slightly positive as it aligns director interests with shareholders.

Positives

• The vesting of restricted stock units indicates that the director has met the conditions for the award.
• The acquisition of shares by a director can be seen as a positive sign of confidence in the company.

Industry Context

This is a routine filing related to the vesting of equity compensation for a company director, which is a common practice in publicly traded companies.

Comparison to Industry Standards

• The vesting of restricted stock units is a standard form of equity compensation for directors and executives in publicly traded companies.
• The number of shares acquired is relatively small, suggesting this is a regular vesting event rather than a significant purchase.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

Palisade Bio, Director, Binxian Wei, Stock Acquisition, Restricted Stock Units, Vesting, SEC Form 4, Beneficial Ownership